Elios Financial Group Inc. Takes $433,000 Position in Eli Lilly and Company (NYSE:LLY)

Elios Financial Group Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 489 shares of the company’s stock, valued at approximately $433,000.

A number of other large investors have also recently added to or reduced their stakes in LLY. Qsemble Capital Management LP acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $2,899,000. Acorn Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 20.5% during the 3rd quarter. Acorn Wealth Advisors LLC now owns 689 shares of the company’s stock valued at $610,000 after buying an additional 117 shares during the last quarter. Wiser Advisor Group LLC increased its position in Eli Lilly and Company by 8.6% during the third quarter. Wiser Advisor Group LLC now owns 1,609 shares of the company’s stock worth $1,426,000 after buying an additional 128 shares in the last quarter. Associated Banc Corp increased its position in Eli Lilly and Company by 13.8% during the third quarter. Associated Banc Corp now owns 26,299 shares of the company’s stock worth $23,299,000 after buying an additional 3,197 shares in the last quarter. Finally, Private Trust Co. NA raised its holdings in shares of Eli Lilly and Company by 1.7% in the third quarter. Private Trust Co. NA now owns 12,289 shares of the company’s stock worth $10,887,000 after acquiring an additional 209 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $755.00 on Tuesday. The company has a market cap of $716.73 billion, a price-to-earnings ratio of 81.62, a price-to-earnings-growth ratio of 2.83 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock’s 50-day moving average is $861.63 and its 200-day moving average is $870.20.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the previous year, the business posted $0.10 EPS. The company’s quarterly revenue was up 20.4% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.69%. Eli Lilly and Company’s payout ratio is 56.22%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on LLY shares. Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Wolfe Research began coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. Finally, Wells Fargo & Company boosted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.